Silence Therapeutics (SLN)
5.63
-0.27 (-4.58%)
At close: Jan 14, 2025, 3:59 PM
5.70
1.24%
After-hours Jan 14, 2025, 07:41 PM EST
undefined% (undefined)
| Bid | 5.61 |
| Market Cap | 265.82M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | -3.43 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.49 |
| Volume | 162,505 |
| Avg. Volume (20D) | 511,163 |
| Open | 5.95 |
| Previous Close | 5.90 |
| Day's Range | 5.58 - 6.10 |
| 52-Week Range | 5.58 - 27.72 |
| Beta | undefined |
About SLN
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 8, 2020
Employees 109
Stock Exchange NASDAQ
Ticker Symbol SLN
Analyst Forecast
According to 4 analyst ratings, the average rating for SLN stock is "Buy." The 12-month stock price forecast is $61, which is an increase of 983.48% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
11 months ago ·
Source
+15.44%
Silence Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
